Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd

<< Previous

Bullboard Posts

Next >>

Post by MrMonkon Oct 24, 2012 9:23pm

266 Views

Post# 20520758

Eye on the prize...

For anyone concerned about the recent price action, remember to keep your eye on the prize. The fundamentals have NOT changed. 2.1 million ounces and Phase 2 results are not included. I don't believe ARZ has formally announced its commitment to Phase 3, however that seems to be a near-certainty and we should hear something on that very soon. And the key takeaway - this thing will be a mine. A small fraction of gold exploration projects become producing mines - a tiny fraction. This will be one of them. I see this as a chance to get some cheap shares.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments